Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Kintara Therapeutics Inc | KTRA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.1373 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.1373 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.081 - 5.98 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.1373 | USD |
Kintara Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.47M | 39.04M | - | 0 | -15.02M | -0.38 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Kintara Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KTRA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.1015 | 0.1442 | 0.101 | 0.1269755 | 4,972,783 | 0.0358 | 35.27% |
| 1 Month | 0.1077 | 0.24 | 0.0925 | 0.1489537 | 18,483,084 | 0.0296 | 27.48% |
| 3 Months | 0.134 | 0.24 | 0.081 | 0.1250206 | 14,256,489 | 0.0033 | 2.46% |
| 6 Months | 4.22 | 4.48 | 0.081 | 0.1442501 | 9,763,391 | -4.08 | -96.75% |
| 1 Year | 3.02 | 5.98 | 0.081 | 0.1843238 | 4,931,620 | -2.88 | -95.45% |
| 3 Years | 78.00 | 142.50 | 0.081 | 10.50 | 2,688,168 | -77.86 | -99.82% |
| 5 Years | 60.50 | 167.50 | 0.081 | 14.99 | 2,310,353 | -60.36 | -99.77% |
Kintara Therapeutics Description
| Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications. |
